Works Cited

Diabetes Pharmacology

Course #95323 - $40 • 10 Hours/Credits

  • Back to Course Home
  • Participation Instructions

1. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract. 2015;21(Suppl 1):S1-S87.

2. Edelman SV, Henry RR. Diagnosis and Management of Type 2 Diabetes. 11th ed. New York, NY: Professional Communications, Inc.; 2011.

3. Mensing C (ed). The Art and Science of Diabetes Self-Management Education: Desk Reference. 4th ed. Chicago, IL: American Association of Diabetes Educators; 2017.

4. Centers for Disease Control and Prevention. Long-Term Trends in Diabetes—April 2017. Available at https://www.cdc.gov/diabetes/statistics/slides/long_term_trends.pdf. Last accessed October 7, 2019.

5. American Diabetes Association. Statistics About Diabetes. Available at https://www.diabetes.org/resources/statistics/statistics-about-diabetes. Last accessed October 7, 2019.

6. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Available at https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Last accessed October 7, 2019.

7. Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practice. 2nd ed. New York, NY: Informa Healthcare; 2008.

8. Centers for Disease Control and Prevention Division of Diabetes Translation. Maps of Trends in Diagnosed Diabetes, April 2017. Available at https://www.cdc.gov/diabetes/statistics/slides/maps_diabetes_trends.pdf. Last accessed October 7, 2019.

9. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Causes of Diabetes. Available at https://www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes?dkrd=hiscr0005. Last accessed October 7, 2019.

10. Centers for Disease Control and Prevention. Prevalence of Total, Diagnosed, and Undiagnosed Diabetes Among Adults: United States, 2013-2016. Available at https://www.cdc.gov/nchs/products/databriefs/db319.htm. Last accessed October 7, 2019.

11. Gebel E. More Kids Than Ever Have Type 2 Diabetes. Available at http://www.diabetesforecast.org/2012/nov/more-kids-than-ever-have-type-2-diabetes.html. Last accessed October 7, 2019.

12. Colberg S, Friesz M. Diabetes-Free Kids: A Take-Charge Plan for Preventing and Treating Type 2 Diabetes in Children. New York, NY: Avery; 2005.

13. Khardori R. Type 1 Diabetes Mellitus. Available at https://emedicine.medscape.com/article/117739-overview. Last accessed October 7, 2019.

14. Childs BP, Cypress M, Cypress M, Spollett G (eds). Complete Nurse's Guide to Diabetes Care. 2nd ed. Alexandria, VA: American Diabetes Association; 2009.

15. American Association of Clinical Endocrinologists, American College of Endocrinology Task Force. AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm, 2019. Available at https://www.aace.com/disease-state-resources/diabetes/clinical-practice-guidelines-treatment-algorithms/comprehensive. Last accessed October 7, 2019.

16. Centers for Disease Control and Prevention. Diabetes Basics. Available at https://www.cdc.gov/diabetes/basics/index.html. Last accessed October 7, 2019.

17. Bardsley JK, Ratner RE. Pathophysiology of the metabolic disorder. In: Mensing C (ed). Art and Science of Diabetes Self-Management Education: Desk Reference. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

18. Kahn CR, Weir GC, King GL, Moses AC, Smith RJ, Jacobson AM. Joslin's Diabetes Mellitus. 14th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004.

19. Arbelaez AM, Powers WJ, Videen TO, Price JL, Cryer PE. Attenuation of counter regulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes. 2008;57(2):470-475.

20. Schneider CA, Erdman E. Acute coronary syndrome, myocardial infarction, heart failure, and stable coronary artery disease: specific consideration in diabetes. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practices. 2nd ed. New York, NY: Informa; 2008: 463-474.

21. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Prevention Program (DPP). Available at https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/diabetes-prevention-program-dpp?dkrd=prspt1922. Last accessed October 7, 2019.

22. U.S. Food and Drug Administration. Archive: Safety. Rezulin (Troglitazone). Available at https://wayback.archive-it.org/7993/20170112171602/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173081.htm. Last accessed October 7, 2019.

23. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Control and Complications Trial (DCCT): DCCT Results. Available at https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/blood-glucose-control-studies-type-1-diabetes-dcct-edic. Last accessed October 7, 2019.

24. Cooppan RM. Rationale and goals for glucose control in diabetes mellitus and glucose monitoring. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practice. 2nd ed. New York, NY: Informa Healthcare; 2008.

25. Skyler JS. Thirty years of diabetes care: reflections on the beginning. Diabetes Care. 2008;31(1):183-184.

26. National Institute of Diabetes and Digestive and Kidney Diseases. Blood Glucose Control Studies for Type 1 Diabetes: DCCT and EDIC. Available at https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/blood-glucose-control-studies-type-1-diabetes-dcct-edic. Last accessed October 7, 2019.

27. UK Prospective Diabetes Study. Available at https://www.dtu.ox.ac.uk/ukpds/. Last accessed October 7, 2019.

28. Holman RR, Paul SK, Bethal MA, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med. 2008;359(15):1577-1589.

29. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086.

30. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736-1747.

31. McMahon GT, Dluhy RG. Intention to treat: initiating insulin and the 4-T study. N Engl J Med. 2007;357(17):1759-1761.

32. ClinicalTrials.gov. The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). Available at https://clinicaltrials.gov/ct2/show/study/NCT00069784. Last accessed October 7, 2019.

33. ORIGIN Trial. ORIGIN At A Glance. Available at http://www.origintrial.org/ORIGIN-at-a-glance/ORIGIN. Last accessed October 7, 2019.

34. Rosenstock J, Kahn SE, Johansen OE. Effect of linagliptin versus glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155-1166.

35. American Diabetes Association. Classification and diagnosis of diabetes mellitus. Diabetes Care. 2019;42(Suppl 1):S13-S28.

36. American Diabetes Association. Gestational Diabetes. Available at https://www.diabetes.org/diabetes/gestational-diabetes. Last accessed October 7, 2019.

37. National Institute of Diabetes and Digestive and Kidney Diseases. Gestational Diabetes. Available at https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/gestational?dkrd=hiscr0003. Last accessed October 7, 2019.

38. Reader DM. Gestational diabetes. In: Mensing C (ed). Art and Science of Diabetes Self-Management Education: Desk Reference. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

39. American Diabetes Association. Gestational Diabetes and a Healthy Baby? Yes. Available at https://www.diabetes.org/diabetes/gestational-diabetes. Last accessed October 7, 2019.

40. American Diabetes Association. Gestational Diabetes: Treatment and Perspective. Available at https://www.diabetes.org/diabetes/gestational-diabetes/how-to-treat-gestational-diabetes. Last accessed October 7, 2019.

41. American Diabetes Association. Standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S1-S193.

42. American Diabetes Association. Position statement: screening for type 2 diabetes. Diabetes Care. 2004;27(suppl 1):S11-S14.

43. MedlinePlus. Diabetes Type 2. Available at https://medlineplus.gov/diabetestype2.html. Last accessed October 7, 2019.

44. American Diabetes Association. What Causes Diabetes? Find Out and Take Control. Available at https://www.diabetes.org/diabetes-risk. Last accessed October 7, 2019.

45. American Diabetes Association. Diagnosis. Available at https://www.diabetes.org/a1c/diagnosis?loc=db-slabnav. Last accessed October 7, 2019.

46. U.S. National Library of Medicine. Sulfonylureas Drug. Available at https://medlineplus.gov/ency/imagepages/19828.htm. Last accessed October 7, 2019.

47. Goroll AH, Mulley AG. Primary Care Medicine. Office Evaluation and Management of the Adult Patient. 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2009.

48. Sisson E. AADE Quick Guide to Medications. 9th ed. Chicago, IL: American Association of Diabetes Educators; 2019.

49. LexiComp Online. Available at https://online.lexi.com/lco/action/login. Last accessed October 7, 2019.

50. Comerford KC (ed). Nursing 2017 Drug Handbook. 37th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2016.

51. RxList. Januvia. Available at https://www.rxlist.com/januvia-drug.htm. Last accessed October 7, 2019.

52. RxList. Amaryl. Available at https://www.rxlist.com/amaryl-drug.htm.. Last accessed October 7, 2019.

53. Diabetes Self-Management. Sulfonylureas. Available at https://www.diabetesselfmanagement.com/diabetes-resources/definitions/sulfonylureas/. Last accessed October 7, 2019.

54. Davis's Drug Guide. Acetohexamide. Available at https://www.drugguide.com/ddo/search?st=OSS&catcode=277&q=Acetohexamide. Last accessed October 7, 2019.

55. RxList. Glucotrol. Available at https://www.rxlist.com/glucotrol-drug.htm. Last accessed October 7, 2019.

56. RxList. Micronase. Available at https://www.rxlist.com/micronase-drug.htm. Last accessed September 16, 2019.

57. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all-cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731.

58. Pladevall M, Riera-Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Cardiovascular risk associated with the use of glitazones, metformin and sulfonylureas: meta-analysis of published observational studies. BMC Cardiovasc Disord. 2016;16:14.

59. Jancin B. Four sulfonylureas tied to deaths in prior MI patients. Clin Endocrinol News. 2009;4(10):1-7.

60. Davidson JK. Clinical Diabetes Mellitus: A Problem-Oriented Approach. 3rd ed. New York, NY: Thieme; 2000.

61. Aquilante CL. Sulfonylurea pharmacogenomics in type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010;8(3):359-372.

62. International Diabetes Federation. IDF Guideline on Self-Monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes. Available at https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/85:self-monitoring-of-blood-glucose-in-non-insulin-treated-type-2-diabetes.html. Last accessed October 7, 2019.

63. RxList. Prandin. Available at https://www.rxlist.com/prandin-drug.htm. Last accessed October 7, 2019.

64. RxList. Nateglinide. Available at https://www.rxlist.com/starlix-drug.htm. Last accessed October 7, 2019.

65. RxList. Precose. Available at https://www.rxlist.com/precose-drug.htm. Last accessed October 7, 2019.

66. RxList. Glyset. Available at https://www.rxlist.com/glyset-drug.htm.. Last accessed October 7, 2019.

67. Daily Med. Available at https://dailymed.nlm.nih.gov/dailymed/index.cfm,. Last accessed October 7, 2019.

68. MedlinePlus. Metformin. Available at https://medlineplus.gov/druginfo/meds/a696005.html. Last accessed October 7, 2019.

69. RxList. Glucophage, Glucophage XR. Available at https://www.rxlist.com/glucophage-drug.htm. Last accessed October 7, 2019.

70. Roumie CL, Chipman J, Min JY. Association of treatment with metformin versus sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA. 2019;322(12):1167-1177.

71. Bristol-Meyers Squibb Company. Glucophase: Glucophage XR. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf. Last accessed October 7, 2019.

72. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Revises Warnings Regarding Use of the Diabetes Medicine Metformin in Certain Patients with Reduced Kidney Function. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain. Last accessed October 7, 2019.

73. RxList. Actos. Available at https://www.rxlist.com/actos-drug.htm. Last accessed October 7, 2019.

74. Mensing C. The role of the diabetes educator in the education and management of diabetes mellitus. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practices. 2nd ed. New York, NY: Informa Healthcare; 2008: 45-57.

75. RxList. Avandia. Available at https://www.rxlist.com/avandia-drug.htm. Last accessed October 7, 2019.

76. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investigation. 2012;1(1-2):8-23.

77. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism. 2013;17(6):819-837.

78. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Three New Drug Treatments for Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023907/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm. Last accessed October 7, 2019.

79. U.S. Food and Drug Administration. Archive: Safety Information. Sitagliptin (Marketed as Januvia and Janumet)—acute pancreatitis. Available at https://wayback.archive-it.org/7993/20170112165806/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm. Last accessed October 7, 2019.

80. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534-539.

81. U.S. Food and Drug Administration. Archive: FDA Drug Safety Podcast. FDA Investigating Reports of Possible Increased Risk of Pancreatitis and Pre-Cancerous Findings of the Pancreas from Incretin Mimetic Drugs for Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170722152428/https://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm344232.htm. Last accessed October 7, 2019.

82. Freeman MK. Efficacy and safety of linagliptin (Tradjenta) in adults with type-2 diabetes mellitus. P T. 2011;36(12):807-812, 842.

83. Bristol-Myers Squibb. Saxagliptin: Highlights of Prescribing Information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022350s004lbl.pdf. Last accessed October 7, 2019.

84. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Adds Warnings About Heart Failure Risk to Labels of Type 2 Diabetes Medicines Containing Saxagliptin and Alogliptin. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes. Last accessed October 7, 2019.

85. Boehringer Ingelheim International. Tradjenta (Linagliptin): Highlights of Prescribing Information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201280lbl.pdf. Last accessed October 7, 2019.

86. U.S. Food and Drug Administration. Archive: Safety Information. Tradjenta (Linagliptin) Tablets: Warnings and Precautions. Available at https://wayback.archive-it.org/7993/20170406125125/https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm319215.htm. Last accessed October 7, 2019.

87. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Invokana to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023858/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Last accessed October 7, 2019.

88. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Farxiga to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023850/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm. Last accessed October 7, 2019.

89. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Jardiance to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023827/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm. Last accessed October 7, 2019.

90. U.S. Food and Drug Administration. Archive: FDA Drug Safety Communication. FDA Warns That SGLT2 Inhibitors for Diabetes May Result in a Serious Condition of Too Much Acid in the Blood. Available at http://wayback.archive-it.org/7993/20170112031553/http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Last accessed October 7, 2019.

91. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about. Last accessed October 7, 2019.

92. U.S. Food and Drug Administration. Archive: FDA Drug Safety Communication. SGLT2 Inhibitors: Drug Safety Communication—Labels to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections. Available at https://wayback.archive-it.org/7993/20170406123608/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm475553.htm. Last accessed October 7, 2019.

93. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Confirms Increased Risk of Leg and Foot Amputations With the Diabetes Medicine Canagliflozin (Invokana, Invokamet, Invokamet XR). Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine#targetText=%5B%205%2D16%2D2017%20%5D,of%20leg%20and%20foot%20amputations. Last accessed October 7, 2019.

94. U.S. Food and Drug Administration. Archive: FDA Drug Safety Communication. Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR): Drug Safety Communication—Strengthened Kidney Warnings. Available at https://wayback.archive-it.org/7993/20171105025100/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm506554.htm. Last accessed October 7, 2019.

95. U.S. Food and Drug Administration. Archive: Safety Announcement. FDA Warns about Rare Occurrences of a Serious Infection of the Genital Area with SGLT2 Inhibitors for Diabetes. Available at https://wayback.archive-it.org/7993/20190207173939/https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm. Last accessed October 7, 2019.

96. Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30(10):1893-1907.

97. U.S. Food and Drug Administration. NDA Approval: Xiduo XR. Available at https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205649Orig1s000ltr.pdf. Last accessed October 7, 2019.

98. Walsh J, Roberts R. Letter to the editor: a study that glucose control can be achieved in 31 type 1 patients who follow a controlled diet and use an insulin pump that is programmed. J Diabetes Sci Technol. 2007;1(4):L3-L6.

99. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves First Automated Insulin Delivery Device for Type 1 Diabetes. Available at https://wayback.archive-it.org/7993/20170111083713/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522974.htm. Last accessed October 7, 2019.

100. Tomky DM, Kulkarni K. Intensifying insulin therapy: multiple daily injections to pump therapy. In: Mensing C (ed). Art and Science of Diabetes Self-Management Education: Desk Reference. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

101. Taber's Online. Available at https://www.tabers.com/tabersonline. Last accessed October 7, 2019.

102. RxList. NovoLog. Available at https://www.rxlist.com/novolog-drug.htm. Last accessed October 7, 2019.

103. O'Keefe JH Jr, Bell DSH, Wyne KL, Haffner SM. Diabetes Essentials. 3rd ed. Royal Oak, MI: Physician's Press; 2007.

104. RxList. Humalog. Available at http://www.rxlist.com/humalog-drug.htm. Last accessed October 7, 2019.

105. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Afrezza to Treat Diabetes. Available at https://wayback.archive-it.org/7993/20170112222845/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122.htm. Last accessed October 7, 2019.

106. RxList. Humulin R. Available at https://www.rxlist.com/humalog-drug.htm. Last accessed October 7, 2019.

107. RxList. Novolin R. Available at https://www.rxlist.com/novolin-r-drug.htm. Last accessed October 7, 2019.

108. Rea RS, Donihi-Calabrese D, Bobeck M, et al. Implementing an intravenous insulin infusion protocol in the intensive care unit. Am J Health Syst Pharm. 2007;64(4):385-395.

109. Dilkhush D, Lannigan J, Pedroff T, Riddle A, Tittle M. Insulin infusion protocol for critical care units. Am J Health Syst Pharm. 2005;62(21):2260-2264.

110. Joslin Diabetes Center. Ketone Testing: What You Need to Know. Available at https://www.joslin.org/info/ketone_testing_what_you_need_to_know.html. Last accessed October 7, 2019.

111. Hamdy O. Diabetic Ketoacidosis. Available at https://emedicine.medscape.com/article/118361-overview. Last accessed October 7, 2019.

112. Rosenbloom AL. Hyperglycemic coma in children. In: Lifshitz F (ed). Pediatric Endocrinology Volume 1: Obesity, Diabetes Mellitus, Insulin Resistance, and Hypoglycemia. 5th ed. New York, NY: Informa Healthcare; 2007: 155-168.

113. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343.

114. Arnold MS, Trence DL. Hyperglycemia. In: Mensing C (ed). Art and Science of Diabetes Self-Management Education: Desk Reference. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

115. Trachtenbarg DE. Diabetic ketoacidosis. Am Fam Phys. 2005;71(9):1705-1714.

116. Kitabchi AE, Umpierrez GE, Murphy MB, Kreisburg RA. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29(12):2739-2748.

117. MedlinePlus. Diabetic Ketoacidosis. Available at https://medlineplus.gov/ency/article/000320.htm. Last accessed October 7, 2019.

118. Avichal D. Hyperosmolar Hyperglycemic State. Available at https://emedicine.medscape.com/article/1914705-overview. Last accessed October 7, 2019.

119. Nugent BW. Hyperosmolar hyperglycemic state. Emerg Med Clin North Am. 2005;23(3):629-648.

120. Joslin Diabetes Center. Sick Days. Available at https://www.joslin.org/info/Sick_Days.html. Last accessed October 7, 2019.

121. RxList. Humulin N. Available at https://www.rxlist.com/humulin-n-drug.htm. Last accessed October 7, 2019.

122. RxList. Levemir. Available at https://www.rxlist.com/levemir-drug.htm. Last accessed October 7, 2019.

123. U.S. Food and Drug Administration. Drug Approval Package. Levemir Insulin Detemir (rDNA Origin) Injection. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021-536_LevemirTOC.cfm. Last accessed October 7, 2019.

124. U.S. Food and Drug Administration. Archive: Press Release. FDA Issues Public Health Advisory Regarding Levemir Insulin. Available at https://wayback.archive-it.org/7993/20170113163915/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm166358.htm. Last accessed October 7, 2019.

125. U.S. Food and Drug Administration. Levemir: Label Information. Available at https://www.accessdata.fda.gov/scripts/cder/daf/. Last accessed October 7, 2019.

126. Cryer PE. Hypoglycemia in type 2 diabetes. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes Principles and Practices. 2nd ed. New York, NY: Informa; 2008: 227-236.

127. Bethel MA, Feinglos MN. Basil insulin therapy in type 2 diabetes. J Am Board Fam Med. 2005;18(3):199-204.

128. Steil CF. Pharmacological therapies for glucose management. In: Mensing C (ed). Art and Science of Diabetes Self-Management Education: Desk Reference. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

129. U.S. Food and Drug Administration. Drugs@FDA. Byetta: Approval History. Available at https://www.accessdata.fda.gov/scripts/cder/daf/#apphist. Last accessed October 7, 2019.

130. RxList. Byetta. Available at https://www.rxlist.com/byetta-drug.htm. Last accessed October 7, 2019.

131. Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010;33(6):1294-1296.

132. U.S. Food and Drug Administration. Questions and Answers: Safety Requirements for Victoza (Liraglutide). Available at https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-safety-requirements-victoza-liraglutide. Last accessed October 7, 2019.

133. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Bjerre Knudsen L. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes. 2007;56(1):8-15.

134. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves New Treatment for Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112024032/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253501.htm. Last accessed October 7, 2019.

135. U.S. Food and Drug Administration. Archive: News Release. FDA Approves Tanzeum to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023843/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393289.htm. Last accessed October 7, 2019.

136. U.S. Food and Drug Administration. Archive: News Release. FDA Approves Trulicity to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023822/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm. Last accessed October 7, 2019.

137. U.S. Food and Drug Administration. Press Release: FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes?utm_campaign=092019_PR_FDA%20approves%20first%20oral%20GLP-1%20treatment%20for%20type%202%20diabetes&utm_medium=email&utm_source=Eloqua. Last accessed October 7, 2019.

138. Karl D, Philis-Tsimikas A, Darsow T, et al. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther. 2007;9(2):191-199.

139. RxList. Symlin. Available at https://www.rxlist.com/symlin-drug.htm. Last accessed October 7, 2019.

140. Mayo Clinic. Hypoglycemia: Symptoms. Available at https://www.mayoclinic.org/diseases-conditions/hypoglycemia/symptoms-causes/syc-20373685. Last accessed October 7, 2019.

141. Down S, Kirkland F. Injection technique in insulin therapy. Nurs Times. 2012;108(10):18-21.

142. Drugs@FDA. Novolin 70/30. Label information. U.S. Food and Drug Administration Web site. Available at https://www.accessdata.fda.gov/scripts/cder/daf/. Last accessed October 7, 2019.

143. U.S. Food and Drug Administration. Symlin (Pramlintide Acetate): Label Information. Available at https://www.accessdata.fda.gov/scripts/cder/daf/. Last accessed October 7, 2019.

144. Kulkarni K. Diets do not fail: the success of medical nutrition therapy in patients with diabetes. Endocr Pract. 2006;12(Suppl 1):121-123.

145. Centers for Disease Control and Prevention. Take Charge of Your Diabetes. 4th ed. Atlanta, GA: U.S. Department of Health and Human Services; 2007.

146. Zinman B, Ruderman N, Campaigne BN, Devlin JT, Schneider SH. Diabetes Mellitus and Exercise. Available at https://www.medscape.com/viewarticle/717051. Last accessed October 7, 2019.

147. Wasserman DH, Zinman B. Exercise in individuals with IDDM. Diabetes Care. 1994;17(8):924-937.

148. Dubé M-C, Weisnagel SJ, Prud'homme D, Lavoie C. Exercise and newer insulins: how much glucose supplement to avoid hypoglycemia? Med Sci Sports Exerc. 2005;37(8):1276-1282.

149. Francescato MP, Geat M, Fusi S, Stupar G, Noacco C, Cattin L. Carbohydrate requirement and insulin concentration during moderate exercise in type 1 diabetic patients. Metabolism. 2004;53(9):1126–1130.

150. Nagi D (ed). Exercise and Sport in Diabetes. 2nd ed. Chichester: John Wiley and Sons, Ltd; 2005.

151. Younk LM, Mikeladze M, Tate D, Davis SN. Exercise-related hypoglycemia in diabetes mellitus. Expert Rev Endocrinol Metab. 2011;6(1):93-108.

152. Joslin Diabetes Center. Joslin Clinical Guideline for Adults with Diabetes (Rev. 05/17/17). Available at https://www.joslin.org/docs/CLINICAL-GUIDELINE-FOR-ADULTS-WITH-DIABETES-Rev-05-17-2017.pdf. Last accessed October 7, 2019.

  • Back to Course Home
  • Participation Instructions